Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
19.02
USD
-0.03 (-0.16%)
Official Closing Price
Updated: 5:20 PM EDT, Apr 9, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Alkermes Honors Black American Pioneers in Mental Health
February 17, 2021
Tags
NASDAQ:ALKS
Alkermes
Workplace Inclusion
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
February 11, 2021
-- Revenues of $1.04 Billion in 2020, GAAP Loss per Share of $0.70 and Basic and Diluted Non-GAAP Earnings per Share of $0.43 --
From
PR Newswire
Keeping Mental Health in Mind During a Pandemic Winter
February 08, 2021
Tags
NASDAQ:ALKS
Alkermes
Exercise & Activity
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
February 04, 2021
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company's fourth quarter and year-end 2020...
From
PR Newswire
Alcohol Use Disorder Treatment and Support Options
February 03, 2021
Tags
Substance Abuse and Mental Health Services Administration (SAMHSA)
Responsible Production & Consumption
Disease Awareness
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Sr. Administrative Assistant Shares Her Motivation and Commitment
February 01, 2021
Tags
Business Ethics
Employee Engagement
Cancer
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alcohol & Your Immune System
January 29, 2021
Tags
Wellness
Responsible Production & Consumption
Good Health and Well/Being
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Sr. Director and Program Lead of Oncology Shares Her Motivation
January 28, 2021
Tags
Disease Awareness
Oncology
Cancer
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Here's What Happens To Your Body After Just One Week Of Dry January
January 25, 2021
Tags
Consumer Engagement
Dry January
Responsible Drinking
From
3BL Media: Corporate Social Responsibility, Energy and Health News
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
January 14, 2021
Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension (XR-NTX) administered once every three...
From
PR Newswire
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morgan Healthcare Conference. The...
From
PR Newswire
Alkermes Announces Updates to Executive Leadership Team
January 06, 2021
-- Blair C. Jackson Appointed Chief Operating Officer and Iain M. Brown Named Chief Financial Officer, Positioning Company for Continued Strong Execution of Business Strategy --
From
PR Newswire
Thinking about buying stock in Immersion Corp, IRIDEX Corp, One Stop Systems, Phio Pharmaceuticals, or Alkermes?
December 29, 2020
InvestorsObserver issues critical PriceWatch Alerts for IMMR, IRIX, OSS, PHIO, and ALKS.
From
PR Newswire
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
December 29, 2020
- FDA Sets PDUFA Target Action Date of June 1, 2021 -
From
PR Newswire
Alkermes Shares Resources for Opioid Addiction
December 29, 2020
Tags
Mobile Health
Opioid Abuse and Addiction
Responsible Business & Employee Engagement
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Resources for Those Managing Alcohol Use Disorder This Holiday Season
December 23, 2020
Tags
Disease Awareness
cdc
Responsible Business & Employee Engagement
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Provides Tips for Managing Holiday Stress
December 22, 2020
Tags
Health & Healthcare
Improving Healthcare Access
NASDAQ:ALKS
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
December 10, 2020
- Commits to Non-GAAP Net Income Margin Targets of ~25% for FY 2023 and ~30% for FY 2024, Reflecting Rigorous Expense Management, Expected Revenue Growth and Commitment to Shareholder Value Creation -
From
PR Newswire
Alkermes Celebrates Giving Tuesday with Alkermes in Action Program
December 03, 2020
Tags
Volunteering
Alkermes
NASDAQ:ALKS
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
November 17, 2020
-- No Clinical Efficacy or Safety Issues Raised and No Further Studies Required by FDA to Support Approval --
From
PR Newswire
Alkermes Celebrates National Family Caregivers Month: Jessica's Story
November 16, 2020
Tags
National Family Caregivers Month
Employee Engagement
Biopolar Disorder
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Recognizes the Value of Veterans
November 13, 2020
Tags
Military
Alkermes
NASDAQ:ALKS
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020
Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
From
Business Wire News Releases
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
November 09, 2020
- Subcutaneous Dosing of ALKS 4230 in ARTISTRY-2 Showed Desired Immune Response and Safety Profile Consistent With the Observed Effects of Intravenous ALKS 4230 -
From
PR Newswire
Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic
November 04, 2020
Tags
Social Impact & Volunteering
Pharma News, Research & Solutions
Good Health and Well/Being
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Resources for Those Recovering From or Struggling With Alcohol Use Disorder
November 02, 2020
Tags
Good Health and Well/Being
alcohol use disorder
Alkermes
From
3BL Media: Corporate Social Responsibility, Energy and Health News
A Meaningful Difference for Cancer Patients and Loved Ones
October 30, 2020
Tags
Alkermes
Cancer
Responsible Business & Employee Engagement
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
October 29, 2020
Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulties impacting the conference call...
From
PR Newswire
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
October 29, 2020
- Company Reports Third Quarter Revenues of $265.0 Million, GAAP Net Loss per Share of $0.00 and Basic and Diluted Non-GAAP Earnings per Share of $0.26 -
From
PR Newswire
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
October 28, 2020
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.